Baker Ellis Asset Management LLC Purchases Shares of 1,980 Cencora, Inc. (NYSE:COR)

Baker Ellis Asset Management LLC purchased a new stake in Cencora, Inc. (NYSE:COR) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 1,980 shares of the company’s stock, valued at approximately $481,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Rise Advisors LLC acquired a new position in Cencora during the first quarter worth $25,000. CVA Family Office LLC acquired a new stake in Cencora in the first quarter valued at $34,000. Bruce G. Allen Investments LLC acquired a new stake in Cencora in the first quarter valued at $43,000. Kathmere Capital Management LLC lifted its stake in Cencora by 15.2% in the first quarter. Kathmere Capital Management LLC now owns 1,498 shares of the company’s stock valued at $364,000 after acquiring an additional 198 shares during the last quarter. Finally, Sunbelt Securities Inc. acquired a new stake in Cencora in the first quarter valued at $67,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have commented on COR shares. SVB Leerink reiterated an “outperform” rating and issued a $275.00 price target on shares of Cencora in a research note on Thursday. StockNews.com cut shares of Cencora from a “strong-buy” rating to a “buy” rating in a research note on Thursday, May 2nd. Citigroup increased their price target on shares of Cencora from $265.00 to $280.00 and gave the company a “buy” rating in a research note on Tuesday, April 30th. Finally, Robert W. Baird raised their target price on shares of Cencora from $275.00 to $277.00 and gave the stock an “outperform” rating in a research note on Thursday, May 2nd. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $235.30.

Cencora Price Performance

NYSE:COR opened at $225.30 on Friday. Cencora, Inc. has a 52 week low of $171.65 and a 52 week high of $246.75. The firm has a market cap of $44.94 billion, a price-to-earnings ratio of 24.65, a P/E/G ratio of 1.57 and a beta of 0.48. The firm’s 50-day simple moving average is $229.12 and its 200 day simple moving average is $227.99. The company has a debt-to-equity ratio of 3.41, a quick ratio of 0.53 and a current ratio of 0.89.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, May 1st. The company reported $3.80 EPS for the quarter, topping analysts’ consensus estimates of $3.65 by $0.15. Cencora had a net margin of 0.67% and a return on equity of 268.67%. The business had revenue of $68.41 billion for the quarter, compared to analyst estimates of $70.60 billion. During the same period last year, the firm earned $3.50 earnings per share. Cencora’s revenue for the quarter was up 7.8% compared to the same quarter last year. As a group, sell-side analysts predict that Cencora, Inc. will post 13.44 earnings per share for the current year.

Cencora Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, May 24th. Investors of record on Friday, May 10th were given a dividend of $0.51 per share. This represents a $2.04 dividend on an annualized basis and a yield of 0.91%. The ex-dividend date of this dividend was Thursday, May 9th. Cencora’s dividend payout ratio is 22.32%.

Insider Buying and Selling

In other Cencora news, EVP Gina Clark sold 1,874 shares of the firm’s stock in a transaction dated Friday, May 31st. The shares were sold at an average price of $223.86, for a total value of $419,513.64. Following the transaction, the executive vice president now directly owns 13,284 shares of the company’s stock, valued at approximately $2,973,756.24. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other Cencora news, EVP Gina Clark sold 1,874 shares of the firm’s stock in a transaction dated Friday, May 31st. The shares were sold at an average price of $223.86, for a total value of $419,513.64. Following the transaction, the executive vice president now directly owns 13,284 shares of the company’s stock, valued at approximately $2,973,756.24. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Steven H. Collis sold 10,754 shares of the firm’s stock in a transaction dated Tuesday, April 16th. The shares were sold at an average price of $237.48, for a total transaction of $2,553,859.92. Following the completion of the transaction, the chief executive officer now directly owns 285,088 shares in the company, valued at $67,702,698.24. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,956,675 shares of company stock valued at $422,352,056. 15.80% of the stock is owned by company insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.